About Cohance Lifesciences Limited

 

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is a technology-led global Contract Development and Manufacturing Organisation (CDMO) that partners with innovators across the full lifecycle—from early‑stage development to large‑scale commercialisation—spanning pharmaceuticals and specialty chemicals. The Company is headquartered in Hyderabad and positions itself as an innovation‑driven platform with end‑to‑end, high‑value solutions for complex chemistries and modalities, including oligonucleotides and antibody‑drug conjugates (ADCs). 

 

Incorporated in 2018, the Company operates with its registered office in Mumbai and corporate office in Hyderabad . Its scale includes 14 plants, seven R&D facilities, 3,500 KL of capacities, a team of 3,000+ and 510+ scientists; Cohance works with 19 of the top 20 global innovators and has brought 16 commercial products across 10 therapeutic areas to market .

 

Cohance’s identity was purpose‑built through strategic integrations. The platform journey began with the acquisition of RA Chem Pharma and subsequently brought together ZCL Chemicals, Avra Laboratories, Suven Pharmaceuticals, Sapala Organics and NJ Bio—uniting API development, specialty chemicals, finished formulations, and cutting‑edge technologies such as ADCs and oligonucleotide platforms . The Ministry of Corporate Affairs approved the change of name from “Suven Pharmaceuticals Limited” to Cohance Lifesciences Limited with effect from May 7, 2025.

 

Cohance serves customers in 25 countries; exports constituted 90.64% of turnover, underscoring a predominantly international footprint. As at March 31, 2025, the Group comprised five subsidiaries (and one associate) .

 

Cohance Lifesciences Limited’s Business Segments (FY25)

 

• Pharma CDMO: 48% contribution to Combined Platform Revenue in FY25.

 

• Specialty Chemicals: 10% contribution to Combined Platform Revenue in FY25.

 

• API+: 42% contribution to Combined Platform Revenue in FY25.

 

• Domestic vs. International: Exports contributed 90.64% of turnover (balance from India).

 

Cohance Lifesciences Limited Key Management

 

• Vivek Sharma, Executive Chairman

 

• Dr V. Prasada Raju, Managing Director

 

• Sudhir Kumar Singh, Chief Executive Officer

 

• Himanshu Agarwal, Chief Financial Officer

 

• Kundan Kumar Jha, Company Secretary

 

Latest Updates on Cohance Lifesciences Limited

 

• Acquisitions: On December 7, 2024, the Company acquired a 56% equity stake in NJ Bio, Inc. for US$ 64.4 million (Rs 547.96 crore), adding deep ADC capabilities such as payload chemistry, linker synthesis, bioconjugation and a dedicated ADC analytical platform. On July 12, 2024, Cohance acquired 51% of Sapala Organics for Rs 258.00 crore, strengthening oligonucleotide building‑block capabilities, with obligations to acquire the remaining interest in tranches.

 

• Identity: The name changed from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited, effective May 7, 2025 .

 

• Merger: Standalone figures for FY2024 were restated due to the merger of Casper Pharma Private Limited with the Company, effective January 1, 2025 .

 

• Footprint and organisation: New facilities were established in Genome Valley, Hyderabad and Princeton, New Jersey, and Cohance institutionalised three focused business units—Pharma CDMO, API+ and Specialty Chemicals—to enhance execution at scale .